Page last updated: 2024-11-01

niceritrol and Hyperlipoproteinemia Type II

niceritrol has been researched along with Hyperlipoproteinemia Type II in 3 studies

Niceritrol: An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.

Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).

Research Excerpts

ExcerptRelevanceReference
"Seventeen patients with heterozygous familial hypercholesterolemia were sequentially treated with: a low cholesterol, fat restricted diet; diet and probucol (500 mg/day); and diet, probucol and niceritrol (1500 mg/day)."1.28New combined therapy of niceritrol and probucol on heterozygous familial hypercholesterolemia. ( Fukushima, N; Ozaki, I; Sakai, T; Setoguchi, Y; Yamamoto, K; Yanagita, T, 1991)
"Niceritrol treatment significantly reduced the Chol/TG ratio in VLDL while no such effect was seen during clofibrate administration."1.26Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease. ( Borberg, J; Gustafsson, IB; Lithell, H; Vessby, B, 1979)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19902 (66.67)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kibata, M1
Ishida, M1
Asano, K1
Uehara, H1
Saito, K1
Fuchimoto, T1
Ugaki, K1
Murakami, H1
Matoba, K1
Kotakemori, Y1
Shirai, K1
Yoshioka, H1
Nanba, M1
Yasuda, M1
Ishizaki, M1
Kitagawa, N1
Ikejiri, K1
Inohara, R1
Lee, BJ1
Saino, S1
Sakado, J1
Matuzaka, H1
Numata, K1
Mandai, M1
Miyake, K1
Nakamura, K1
Vessby, B1
Lithell, H1
Gustafsson, IB1
Borberg, J1
Yamamoto, K1
Fukushima, N1
Ozaki, I1
Setoguchi, Y1
Yanagita, T1
Sakai, T1

Other Studies

3 other studies available for niceritrol and Hyperlipoproteinemia Type II

ArticleYear
Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia.
    Atherosclerosis, 1980, Volume: 37, Issue:3

    Topics: Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hypolipide

1980
Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Atherosclerosis, 1979, Volume: 33, Issue:4

    Topics: Adult; Aged; Arteriosclerosis; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipopr

1979
New combined therapy of niceritrol and probucol on heterozygous familial hypercholesterolemia.
    Artery, 1991, Volume: 18, Issue:3

    Topics: Adult; Aged; Apolipoproteins A; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL;

1991